Pfizer ’s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
The disappointing data Pfizer announced on its obesity pill are opening up opportunities for biotechs developing their own oral weight-loss drugs. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Cramer on Monday's market action: Some investors are headed for a'nasty hangover '
CNBC's Jim Cramer on Monday suggested that investors are not buying with a clear head and are choosing too many poorly-performing stocks. "I saw a hammered market, a market where the buyers have gotten drunk as a proverbial skunk, buying the worst of the worst," he said. "And when you get…#jimcramer #esteelauder #beauty #moderna #pfizer #postcovid (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects
Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline. (Source: World Pharma News)
Source: World Pharma News - December 4, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
DNA Sequence In Pfizer COVID-19 Vaccine Could Spur New Lawsuits: Lawyers
Authored by Zachary Stieber via The Epoch Times (emphasis ours), Pfizer and its partner BioNTech could be open to lawsuits for including a DNA sequence in their COVID-19 vaccine. A woman walks by Pfizer's headquarters in New…#covid19vaccine #zacharystieber #epochtimes #pfizer #newyorkcity #kenabetancurafp #publicreadiness #prepact #matstaver #libertycounsel (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Pfizer' s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients…#pfizer #danuglipron #obese #novonordisk #elililly #mounjaro #eisai #fda #lorcaserin #belviq (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2023 Category: Consumer Health News Source Type: news
Ticker: Alaska Air to buy Hawaiian Airlines; Pfizer nixes study of obesity pill treatment
Alaska Air Group said Sunday it agreed to buy Hawaiian Airlines in a $1.9 billion deal including debt. The combined company would keep both airlines’ brands, which call the 49th and 50th states their homes. Alaska will pay $18 in cash for each share of Hawaiian, whose stock closed Friday at $4.86.…#alaskaairgroup #hawaiianairlines #alaska #hawaiian #hawaiianholdings #pfizer #novonordisk #elililly #novo (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2023 Category: Consumer Health News Source Type: news
Pfizer Cancels New Weight Loss Pill After Patients Experience Serious Side Effects
Pfizer's new experimental weight-loss pill worked in achieving its stated goal — but with that weight loss came side effects so gnarly that it's shutting down the research. In a press release, the pharmaceutical giant said it was discontinuing clinical trials for danuglipron, its twice-daily…#pfizer #ozempic #danuglipron #glp1 #mikaeldolsten (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2023 Category: Consumer Health News Source Type: news
Texas sues Pfizer over vaccine effectiveness claims
Texas Attorney General Ken Paxton filed a state lawsuit against pharmaceutical company Pfizer on Thursday, accusing the bio-med giant of misrepresenting the efficacy of its COVID-19 vaccine. Paxton alleges Pfizer misled users when claiming the vaccine has a 95 percent effectiveness because of…#kenpaxton #pfizer #paxton (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2023 Category: Consumer Health News Source Type: news
Texas Attorney General Ken Paxton sues Pfizer over vaccine claims
Texas Attorney General Ken Paxton is suing Pfizer, accusing the pharmaceutical company of lying about how effective its Covid-19 vaccine was and of not ending the pandemic as it had suggested. "The COVID-19 vaccines are the miracle that wasn’t," according to the lawsuit, filed in Lubbock County…#kenpaxton #lubbockcounty #pfizer #texastribune #gregabbott #texasstateguard #paxton (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2023 Category: Consumer Health News Source Type: news
‘It wouldn’t exist’: Viagra inventor tells how Welsh miners began its rise
Dr David Brown says erectile dysfunction drug, subject of a BBC drama, could have been scrapped if a miner hadn ’t spoken outIt was the ultimate serendipitous discovery: a failed heart medication that became a multibillion-dollar erectile dysfunction drug. But the blockbuster story ofViagra could have ended differently were it not for the frankness of the Welsh miners who took part in a clinical trial just before the drug was due to be scrapped, according to Viagra ’s co-inventor.Speaking before the screening ofMen Up, a new BBC drama, executive produced by Russell T Davies, about the ordinary middle-aged Welsh men who...
Source: Guardian Unlimited Science - December 2, 2023 Category: Science Authors: Hannah Devlin Science correspondent Tags: Viagra Medical research Men's health Sex Pfizer Wales BBC Russell T Davies Pharmaceuticals industry Society UK news Source Type: news
Did Elon Musk's'GFY' Tirade Accelerate Pivot In Advertising Strategy?
Did Elon Musk's 'GFY' Tirade Accelerate Pivot In Advertising Strategy? On Thursday we emphasized in a note titled "Time To Boycott Elon's Boycotters" that when mega-corporations advertise on social media platforms or news websites, it's often less about traditional advertising and more about…#elonmusk #gfy #moderna #pfizer #dealbookconference #watchelon #nelsonepega #disney #ibm #apple (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2023 Category: Consumer Health News Source Type: news
Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous
FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. Pfizer shares sank Friday, Dec. 1, 2023, when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking…#pfizer #apphoto #marklennihan #novonordisk #elililly #novo #obese #elilillys #mikaeldolsten #danuglipron (Source: Reuters: Health)
Source: Reuters: Health - December 1, 2023 Category: Consumer Health News Source Type: news
Why Pfizer's stumble in the obesity market is a boon for Eli Lilly
has suffered another setback in its efforts to develop a weight-loss pill — and that's good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron,…#club #elililly #lly #pfizer #jimcramer #sp500 #ytd #danish #novonordisk #nvo (Source: Reuters: Health)
Source: Reuters: Health - December 1, 2023 Category: Consumer Health News Source Type: news
Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous
Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it (Source: ABC News: Health)
Source: ABC News: Health - December 1, 2023 Category: Consumer Health News Tags: Health Source Type: news
